Satsuma Pharmaceuticals goes public
Satsuma Pharmaceuticals Inc, which is focused on treating migraines, has raised $82.5 million for its IPO after pricing its 5.5 million shares at $15 per share. The stock began trading September 13, 2019 on the NASDAQ under the ticker symbol "STSA." Credit Suisse, SVB Leerink and Evercore ISI are the lead underwriters. Satsuma's pre-IPO backers include RA Capital Management and TPG Biotech.
13 September 2019•2 mins read
